Supernus Pharmaceuticals, Inc. - Common Stock (SUPN)

Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) to Indivior Pharmaceuticals, Inc. for 1.5401 common shares of Indivior for each share of Supernus.

ROCKVILLE, Md., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for the second quarter 2026 and associated Company developments.

ROCKVILLE, Md. and RICHMOND, Va., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) and Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that they have entered into a definitive agreement to combine in a tax-free all-stock merger of equals transaction to create a leading diversified, central nervous system (CNS) biopharmaceutical company with significant scale. The transaction is expected to generate significant value for stockholders of both companies, realizing $125 million in expected annual cost synergies. The combined entity will be named Supernus, Inc. and will be listed on the Nasdaq Global Market under the ticker symbol “SUPN”. Upon completion of the transaction, Jack Khattar, Supernus Pharmaceuticals President and Chief Executive Officer, will serve as President, Chief Executive Officer and a member of the Board of Directors of the combined company, and Tony Kingsley, a member of Indivior’s Board of Directors, will serve as Board Chair of the combined company.

ROCKVILLE, Md., July 22, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it will report second quarter 2026 financial and business results after the market closes on Tuesday, August 4, 2026.

ROCKVILLE, Md., July 14, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, celebrates the five-year anniversary of the U.S. Food and Drug Administration (FDA) approval of Qelbree (viloxazine extended-release capsules) for attention-deficit/hyperactivity disorder (ADHD). Since its initial approval for pediatric (6 to 17 years) ADHD in April 2021, and subsequent approval for adults in April 2022, Qelbree has served as a valuable option for the nearly 16 million adults and 7 million children and teens living with ADHD in the U.S.,1,2 showcasing Supernus’ 25+ year legacy in ADHD research.

ROCKVILLE, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that management will participate in the following June investor conferences:

ROCKVILLE, Md., May 06, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the Bank of America 2026 Health Care Conference on Tuesday, May 12, 2026, at 3:40 p.m. PT (6:40 p.m. ET) at the Encore Hotel in Las Vegas, NV.

ROCKVILLE, Md., May 05, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for the first quarter 2026 and associated Company developments.

ROCKVILLE, Md., April 22, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it will report first quarter 2026 financial and business results after the market closes on Tuesday, May 5, 2026.

ROCKVILLE, Md., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for the fourth quarter and full year 2025 and associated Company developments.

ROCKVILLE, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that management will participate in the following March investor conferences:

BioMedWire Editorial Coverage: Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical companies are prioritizing de-risked, late-stage assets with human clinical validation rather than speculative early-stage programs. After years of capital flowing into preclinical platforms with uncertain timelines, investors and acquirers are gravitating toward programs with established safety and efficacy data that can accelerate commercialization pathways. This evolving landscape naturally places companies such as Oncotelic Therapeutics Inc. (OTCQB: OTLC) ( Profile ), which holds multiple clinical-stage and late-stage programs across oncology and central nervous system (“CNS”) indications, into focus as strategic assets aligned with current M&A priorities. The company just announced key advancements in its global intellectual property portfolio supporting OT-101, its proprietary TGF-β antisense therapeutic platform. The advancements strengthen protection across neurology, oncology and central nervous system (“CNS”) drug delivery designed to delivery drugs into the brain by getting through the blood brain barrier. This M&A trend bolsters Oncotelic Therapeutics’ position in the oncology and CNS sectors as the OTLC joins other companies focused on the space, including Arrowhead Pharmaceuticals Inc . (NASDAQ: ARWR), MeiraGTx Holdings plc (NASDAQ: MGTX), Supernus Pharmaceuticals Inc. (NASDAQ: SUPN) and…

AUSTIN, Texas, Feb. 17, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical companies are prioritizing de-risked, late-stage assets with human clinical validation rather than speculative early-stage programs. After years of capital flowing into preclinical platforms with uncertain timelines, investors and acquirers are gravitating toward programs with established safety and efficacy data that can accelerate commercialization pathways. This evolving landscape naturally places companies such as Oncotelic Therapeutics Inc. (OTCQB: OTLC) (profile), which holds multiple clinical-stage and late-stage programs across oncology and central nervous system (CNS) indications, into focus as strategic assets aligned with current M&A priorities. The company just announced key advancements in its global intellectual property portfolio supporting OT-101, its proprietary TGF-β antisense therapeutic platform. The advancements strengthen protection across neurology, oncology and central nervous system (CNS) drug delivery designed to deliver drugs into the brain by getting through the blood brain barrier. This M&A trend bolsters Oncotelic Therapeutics’ position in the oncology and CNS sectors as OTLC joins other companies focused on the space, including Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR), MeiraGTx Holdings plc (NASDAQ: MGTX), Supernus Pharmaceuticals Inc. (NASDAQ: SUPN) and Johnson & Johnson (NYSE: JNJ).

ROCKVILLE, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report fourth quarter and full year 2025 financial and business results after the market closes on Tuesday, February 24, 2026.

ROCKVILLE, Md., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will present at the Bank of America Securities 2025 CNS Therapeutics Virtual Conference on Monday, December 8, 2025, at 3:20 p.m. ET.

ROCKVILLE, Md., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025, at 4:00 p.m. ET at the Lotte New York Palace in New York City.

ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the 2025 Jefferies Global Healthcare Conference in London on Monday, November 17, 2025, at 9:30 a.m. EST (2:30 p.m. GMT).

ROCKVILLE, Md., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for the third quarter 2025 and associated Company developments.

ROCKVILLE, Md., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report third quarter 2025 financial and business results after the market closes on Tuesday, November 4, 2025.

CAMBRIDGE, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) --  Biogen Inc. (Nasdaq: BIIB) announced that the European Commission (EC) has granted marketing authorization for ZURZUVAE® (zuranolone) to treat post-partum depression (PPD) in adults following childbirth. ZURZUVAE is a once-daily, oral, 14-day treatment which represents a novel therapeutic approach, offering the first and only treatment indicated for PPD in the E.U.

ROCKVILLE, Md., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today management will participate in the following September investor conferences:

ROCKVILLE, Md., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for the second quarter 2025 and associated Company developments.

Acquisition strengthens Supernus’ leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® (zuranolone), and a novel CNS discovery platform, accelerating mid- to long-term revenue and cash flow growth and further diversifying revenue base

ROCKVILLE, Md., July 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc., a Delaware corporation (NASDAQ: SUPN) ("Supernus", and the "Company"), today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR Act"), with respect to Supernus’ proposed acquisition of Sage Therapeutics, Inc., a Delaware corporation (NASDAQ: SAGE) ("Sage"), expired at 11:59 p.m. Eastern Time on July 25, 2025.

ROCKVILLE, Md., July 22, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the second quarter of 2025 after the market closes on Tuesday, August 5, 2025.